{"ticker": {"uuid": "17ccdeef-e454-4007-ac3a-b32050f8379c", "symbol": "BEAM", "name": "Beam Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Understanding the Setup: (BEAM) and Scalable Risk", "summary": "This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM), noting weak near and mid-term sentiment despite a positive long-term outlook. It highlights that a breakdown is underway with expected lower levels and elevated downside risk. The analysis provides institutional trading", "url": "https://news.stocktradersdaily.com/news_release/141/Understanding_the_Setup:_BEAM_and_Scalable_Risk_071726093801_1784295481.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-17T09:41:42", "published_display": "17 Jul 2026 09:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Beam Therapeutics Stock 6-Day Losing Spree: Stock Falls 19%", "summary": "Beam Therapeutics (NASDAQ: BEAM) stock has experienced a significant downturn, falling 19% over a six-day losing streak. This article reports on the stock's recent performance.", "url": "https://www.trefis.com/data/companies/BEAM/no-login-required/hClH0DhR/Beam-Therapeutics-Stock-6-Day-Losing-Spree-Stock-Falls-19-", "source_name": "Trefis", "published_at": "2026-07-16T15:40:25", "published_display": "16 Jul 2026 15:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6 Red Days In A Row: Beam Therapeutics Stock Is Down 19%", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPSHE5Nl9xLXJwNTd4X054WTMzMGNoYlhDb1pNWnVTSGMxdzdXYm5GNGVwZFBVRW1xaXdBM1cybVI5a1BwNTlPV295R3paMXVoSHlwZjF1NFJlWXptSlM1VGk3NjRuUE9xUlhQRFoyd1pEVU04ZnRQV1JJM0V0enVSSVZwUVItYlMwZEhIUDllZmxfd2hMcWwzUy15dGpIU1hiUm1PYTlETWZWdzZQTUhHQ0pPRXdpdw?oc=5", "source_name": "Trefis", "published_at": "2026-07-16T14:32:02+00:00", "published_display": "16 Jul 2026 14:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)", "summary": "Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating for Beam Therapeutics (BEAM) with a $47 target price, citing the limited impact of a recent arbitration resolution on Prime Medicine's PM647. The focus for Beam is now on the execution of its alpha-1 antitr", "url": "https://finance.yahoo.com/healthcare/articles/bank-america-securities-maintains-buy-140153544.html", "source_name": "Market source", "published_at": "2026-07-15T14:19:18", "published_display": "15 Jul 2026 14:19", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics", "summary": "Prime Medicine, Inc. (PRME) announced a positive, binding resolution to its arbitration with Beam Therapeutics regarding their 2019 Collaboration and License Agreement. The Tribunal ruled that Prime Medicine's investigational drug PM647 is within its \"Field\" as defined by the Agr", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-prme-reaches-positive-085317803.html", "source_name": "Market source", "published_at": "2026-07-15T09:12:46", "published_display": "15 Jul 2026 09:12", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE9UcXpfZTFzbjNuSnRscl80ekxhdmIycmN5dzNkZFNjeWVpRFV5dlE3VzRVNDNWOUwxN2w0cm1LYWZkQVlqNkJ4ZDZwdjNpYlBoTFo2MVM4ZU1oQ00?oc=5", "source_name": "ChartMill", "published_at": "2026-07-13T16:55:03+00:00", "published_display": "13 Jul 2026 16:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PRME Surges 15% After Winning Arbitration Against Beam \u2014 Clears Path To Human Trials For Its Gene-Editing Drug", "summary": "Prime Medicine (PRME) shares surged 15% after an independent arbitration panel ruled in its favor against Beam Therapeutics (BEAM). The ruling allows Prime to advance its experimental gene-editing drug, PM647, for Alpha-1 Antitrypsin Deficiency, with human trials anticipated in Q", "url": "https://stocktwits.com/news-articles/markets/equity/prme-stock-surges-after-winning-arbitration-against-beam-clears-path-to-human-trials-for-gene-editing-drug/cZmVDItR7NC", "source_name": "Stocktwits", "published_at": "2026-07-12T04:10:08", "published_display": "12 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Sinks 13%: Here\u2019s Why", "summary": "", "url": "https://finance.yahoo.com/m/57b629c0-9b57-300d-bab5-69e9c31cc364/kyverna-therapeutics-sinks.html", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T19:59:59+00:00", "published_display": "10 Jul 2026 19:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics Inc. (BEAM) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Beam Therapeutics Inc. (BEAM) stock, showing a current price of $36.02, up $0.20 (0.57%). It also notes that there are no analyst ratings or earnings information currently available for BEAM. The page is hosted by a platform focused o", "url": "https://timothysykes.com/quote/BEAM/", "source_name": "timothysykes.com", "published_at": "2026-07-09T23:10:57", "published_display": "09 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/beam-therapeutics-beam-faces-aatd-201410556.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T20:14:10+00:00", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable (PRME)", "summary": "Prime Medicine (PRME) recently won an arbitration ruling against Beam Therapeutics regarding its PM647 gene editing program for AATD, causing a surge in its stock. While Prime Medicine's platform offers precision, its programs are still preclinical, with clinical data expected in", "url": "https://seekingalpha.com/article/4920898-prime-medicine-beats-beam-therapeutics-in-patent-dispute-but-both-are-investable", "source_name": "Seeking Alpha", "published_at": "2026-07-09T14:44:28", "published_display": "09 Jul 2026 14:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM) On Tribunal Clarity Is It A Buying Opportunity Or Priced In", "summary": "Beam Therapeutics (BEAM) recently saw its share price rise after a tribunal clarified its collaboration with Prime Medicine, removing monetary risk and clarifying program rights. While narrative analysis suggests the stock is 75% undervalued with a $150 fair value based on its \"m", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/beam-therapeutics-beam-on-tribunal-clarity-is-it-a-buying-op", "source_name": "Simply Wall Street", "published_at": "2026-07-09T10:40:04", "published_display": "09 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BEAM Reiterated by B of A Securities -- Price Target Maintained at $47", "summary": "B of A Securities has reiterated a \"Buy\" rating for Beam Therapeutics (BEAM), maintaining a price target of $47.00, despite the stock being currently valued as 29.6% overvalued by GuruFocus's GF Value\u2122. The company's GF Score\u2122 is 69/100, showing strong financial stability and mom", "url": "https://www.gurufocus.com/news/8950290/beam-reiterated-by-b-of-a-securities-price-target-maintained-at-47", "source_name": "GuruFocus", "published_at": "2026-07-08T23:11:21", "published_display": "08 Jul 2026 23:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-receives-favorable-ruling-180823492.html", "source_name": "MT Newswires", "published_at": "2026-07-08T18:08:23+00:00", "published_display": "08 Jul 2026 18:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise", "summary": "Prime Medicine received a favorable ruling in a license arbitration against Beam Therapeutics, leading to a rise in Prime Medicine's shares. This article provides a brief update on this development and lists recent news related to Beam Therapeutics, including its inclusion in var", "url": "https://www.marketscreener.com/news/prime-medicine-receives-favorable-ruling-in-beam-therapeutics-license-arbitration-shares-rise-ce7f5ed9dd88f723", "source_name": "marketscreener.com", "published_at": "2026-07-08T18:09:00", "published_display": "08 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-receives-favorable-ruling-160256429.html", "source_name": "MT Newswires", "published_at": "2026-07-08T16:02:56+00:00", "published_display": "08 Jul 2026 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine wins binding arbitration against Beam Therapeutics", "summary": "Prime Medicine has won a binding legal arbitration dispute against Beam Therapeutics regarding the genetic asset PM647, confirming the development platform falls entirely within Prime Medicine's contractual field. The company will face zero damage penalties and plans to file clin", "url": "https://grafa.com/en/news/united-states/prime-medicine-arbitration-win-beam-therapeutics", "source_name": "grafa.com", "published_at": "2026-07-08T16:11:21", "published_display": "08 Jul 2026 16:11", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Beam Therapeutics stock sliding today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZlA3UmdRSW5nTW5lUFJqdVBueDN2TjRmSVNOSnZrLWFEWVJ2QW1WOWN6ZzdUQXhicllHakI4d3o1S1pVQk15bTR1X3RIeG9ZVkJPcFRxTWZtdFVxZFBoUHl6LUtlMy1ZVDIydDBjQUl6VHF6a1Y1VkZ0aktFVXhYT0dTNkZ5em0zQ29DMnlxQW40dV94SURpVjJ4WWd6clBKYVp6M08xY0Q2Zw?oc=5", "source_name": "Investing.com", "published_at": "2026-07-08T14:56:42+00:00", "published_display": "08 Jul 2026 14:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-announces-positive-resolution-120000702.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T12:00:00+00:00", "published_display": "08 Jul 2026 12:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQM0lEeVE2U2lnc1ZjdmdjejktdmtuX29VV3Y2U084UDBhdldtakp0WXI4LUIwVVNPX09LanJMWnZEdHVWUWhGR29fcUlOOFMyNUFsMFdoNk5oaGZVVUZiUXZMeUE4UnA5dllkWlVrZjNRQmZZTmliSGhvSExMYldwWTZIWFJKeDd6eFZvRkpTd3RoMDNNV0xtdEZ0dXUtMHF5blFpcEhfek5JdkRVOUVFU0tFeU9HWDFFR1E1SU1JOUM?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Russell Value Index Additions Could Be A Game Changer For Beam Therapeutics (BEAM)", "summary": "Beam Therapeutics (BEAM) was recently added to several Russell Value indices in late June 2026, which is expected to influence trading activity as index-tracking funds adjust their portfolios. While this broad inclusion may impact liquidity and ownership, the company's investment", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/russell-value-index-additions-could-be-a-game-changer-for-be", "source_name": "Simply Wall Street", "published_at": "2026-07-07T07:40:52", "published_display": "07 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics stock hits 52-week high at 36.89 USD", "summary": "Beam Therapeutics Inc. (BEAM) stock has surged to a new 52-week high of $36.89, currently trading at $37.02, reflecting a 90.88% increase over the past year. This growth is attributed to investor confidence in its genetic medicine approaches and recent positive developments, incl", "url": "https://www.investing.com/news/company-news/beam-therapeutics-stock-hits-52week-high-at-3689-usd-93CH-4777036", "source_name": "Investing.com", "published_at": "2026-07-06T16:39:44", "published_display": "06 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC Reduces Stake in Beam Therapeutics Inc.", "summary": "FMR LLC significantly reduced its stake in Beam Therapeutics Inc. by 86.38%, selling over 10 million shares at $35.24 each. Despite this reduction, Beam Therapeutics still represents 1.65% of FMR LLC's holdings, indicating continued belief in the biotechnology company. Beam Thera", "url": "https://www.gurufocus.com/news/8944610/fmr-llc-reduces-stake-in-beam-therapeutics-inc", "source_name": "GuruFocus", "published_at": "2026-07-04T00:39:41", "published_display": "04 Jul 2026 00:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (NASDAQ: BEAM) CMO sells 373 shares for tax withholding", "summary": "Amy Simon, Chief Medical Officer at Beam Therapeutics Inc. (NASDAQ: BEAM), sold 373 shares of common stock for $34.73 each. This non-discretionary transaction was undertaken to cover tax withholding obligations associated with the vesting of restricted stock units granted under t", "url": "https://www.stocktitan.net/sec-filings/BEAM/form-4-beam-therapeutics-inc-insider-trading-activity-11ef9f696223.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:09:15", "published_display": "02 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Following FDA Clearance, Is Beam Therapeutics (BEAM) Already Priced In?", "summary": "Beam Therapeutics (BEAM) has seen its investigational new drug application for BEAM-304 cleared by the FDA, allowing a Phase 1/2 trial to proceed for phenylketonuria patients. Despite a strong share price performance over the past year, the article explores whether the stock, cur", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/following-fda-clearance-is-beam-therapeutics-beam-already-pr", "source_name": "Simply Wall Street", "published_at": "2026-07-02T10:09:15", "published_display": "02 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BEAM - Beam Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial overview for Beam Therapeutics Inc. (BEAM). It includes detailed financial metrics such as market capitalization, income, sales, EPS, P/E ratios, employee count, and stock performance data, offering a snapsh", "url": "https://finviz.com/stock?t=BEAM&p=d&ty=lf&b=2&r=m6&page=9", "source_name": "Finviz", "published_at": "2026-07-02T10:09:15", "published_display": "02 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM) CEO exercises options and sells 50K shares under plan", "summary": "Beam Therapeutics (BEAM) CEO John M. Evans exercised options for 50,000 shares and subsequently sold the same number of shares through open-market transactions at weighted average prices in the mid-$30s. These transactions were carried out under a pre-arranged Rule 10b5-1 trading", "url": "https://www.stocktitan.net/sec-filings/BEAM/form-4-beam-therapeutics-inc-insider-trading-activity-092139809100.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:39:41", "published_display": "01 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BEAM (NASDAQ: BEAM) insider files to sell 25,000 shares via option exercise", "summary": "An insider at Beam Therapeutics Inc. (NASDAQ: BEAM) filed a Form 144 to sell 25,000 common shares through a stock option exercise on June 29, 2026. This regulatory filing indicates an intent to sell, and similar prior transactions by John M. Evans were detailed, including sales i", "url": "https://www.stocktitan.net/sec-filings/BEAM/144-beam-therapeutics-inc-sec-filing-72b474ad91a7.html", "source_name": "Stock Titan", "published_at": "2026-06-30T08:42:59", "published_display": "30 Jun 2026 08:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "25,000-share Rule 144 notice by BEAM (NASDAQ: BEAM) shows option exercise and prior sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOX3J6ZFEzV0c5ZFpvdXRPbjdPWGd6QTVQclRYNnp0ZUJnRzVBYWNaME1nQ0dKcG5zS1pWYzNWNzBrYWxzMnphLS1xLTJnODJwQUFrRW1IaG1aOW5saGNFWC1vZnNoblR5S19XSkhXZV9XSUtnY2lCU2hIV1lSNW1PZzVwVTVJZ3R2TUt3WEd3alpJWkZOTUxTa1cxM2VfSnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics(BEAM.US) 10% Shareholder Sells US$10.04 Million in Common Stock", "summary": "A 10% shareholder of Beam Therapeutics (BEAM.US) recently sold a significant amount of common stock, totaling US$10.04 million. This transaction indicates a notable insider sale that could be of interest to investors tracking company performance.", "url": "https://www.moomoo.com/news/post/72206765/beam-therapeutics-beamus-10-shareholder-sells-us-10-04-million", "source_name": "Moomoo", "published_at": "2026-06-29T20:42:59", "published_display": "29 Jun 2026 20:42", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC sells $10.04 million in Beam Therapeutics shares", "summary": "FMR LLC, a major shareholder, recently sold Beam Therapeutics Inc. (NASDAQ:BEAM) shares worth approximately $10.04 million in late June, with sales occurring at weighted average prices between $35.12 and $35.26. The stock is trading near its 52-week high after a 107% gain over th", "url": "https://www.investing.com/news/insider-trading-news/fmr-llc-sells-1004-million-in-beam-therapeutics-shares-93CH-4766015", "source_name": "Investing.com", "published_at": "2026-06-29T18:40:37", "published_display": "29 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC (BEAM) trims Beam Therapeutics stake with 284,860-share open-market sale", "summary": "FMR LLC, a significant owner of Beam Therapeutics Inc., reported trimming its stake by selling a total of 284,860 common shares through indirect open-market sales. These sales, executed via F-Prime Capital Partners Healthcare Fund V LP on June 25th and 26th, 2026, were valued at ", "url": "https://www.stocktitan.net/sec-filings/BEAM/form-4-beam-therapeutics-inc-insider-trading-activity-a69c1d542de0.html", "source_name": "Stock Titan", "published_at": "2026-06-29T18:40:37", "published_display": "29 Jun 2026 18:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How FDA Clearance of BEAM-304\u2019s Platform Trial for PKU May Impact Beam Therapeutics (BEAM) Investors", "summary": "Beam Therapeutics announced FDA clearance for its BEAM-304 IND application for PKU, featuring a platform-style trial designed to test multiple base editors within a single clinical framework. While this strengthens Beam's in vivo liver editing story and provides a near-term clini", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/how-fda-clearance-of-beam-304s-platform-trial-for-pku-may-im", "source_name": "Simply Wall Street", "published_at": "2026-06-26T22:10:30", "published_display": "26 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics, Inc. Actuals & Estimates (NASDAQ:BEAM)", "summary": "This article provides financial actuals and estimates for Beam Therapeutics Inc. (NASDAQ:BEAM), offering insights into its stock performance, analyst forecasts, and company financials. It details BEAM's current stock price, market capitalization, historical highs and lows, and up", "url": "https://www.tradingview.com/symbols/NASDAQ-BEAM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:40:37", "published_display": "26 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics, Inc. Actuals & Estimates (BMV:BEAM)", "summary": "This article provides financial actuals and estimates for Beam Therapeutics, Inc. (BEAM) traded on the Mexican Stock Exchange (BMV). It details current stock price, historical performance, analyst forecasts, volatility, market capitalization, and upcoming earnings reports. Key fi", "url": "https://www.tradingview.com/symbols/BMV-BEAM/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T05:09:43", "published_display": "26 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM) Short Interest & Short Float | Updated Jun 2026", "summary": "Beam Therapeutics (BEAM) saw its short interest increase by 31.94% to 28.31 million shares as of June 15, 2026, representing 28.60% of its public float. The short interest ratio or \"days to cover\" stands at 14.2, indicating strong pessimism among investors. This article provides ", "url": "https://www.marketbeat.com/stocks/NASDAQ/BEAM/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-25T20:11:06", "published_display": "25 Jun 2026 20:11", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Beam Therapeutics Inc. \u2013 NASDAQ:BEAM", "summary": "The article focuses on the \"Price to sales forward\" metric for Beam Therapeutics Inc. (NASDAQ: BEAM). It provides a high-level view of this financial data point, indicating it is one of the many financial details available for the company on the TradingView platform. The content ", "url": "https://www.tradingview.com/symbols/NASDAQ-BEAM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:41:56", "published_display": "25 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (BEAM) That Institutions Follow", "summary": "This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM) through the lens of technical signals, highlighting strong sentiment across all horizons and an exceptional risk-reward setup targeting a 16.8% gain. It details three AI-generated trading strategies\u2014Position, Momentum Br", "url": "https://news.stocktradersdaily.com/news_release/101/The_Technical_Signals_Behind_BEAM_That_Institutions_Follow_062526010601_1782363961.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-25T01:06:00", "published_display": "25 Jun 2026 01:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM) Could Be 78% Undervalued As FDA Clears BEAM 304", "summary": "Beam Therapeutics (BEAM) is under investor focus after the FDA cleared its investigational new drug application for BEAM-304, an in vivo base editing therapy. The stock is currently trading at US$33.20, while a narrative fair value suggests it could be 77.9% undervalued at $150. ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/beam-therapeutics-beam-could-be-78-undervalued-as-fda-clears", "source_name": "Simply Wall Street", "published_at": "2026-06-24T17:40:20", "published_display": "24 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 93, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics president exercises 35,505 options | BEAM Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNcGItMFJvTGZ3d2p4RGlSdnpkY1RpcG9pNG80cm5SZ283VHp1VHRRdmk5QnZxT3Y3eTFMaXI5dGxuWjFySkRhdGpsQS1Nb2tMRFNVc0c4WjNaS2ZLdHpRX2FIZmdYUHhUcUFnRkFvSmxKTmpXTVlHUlVSTmduT2pQS0NlcElvMEpUMHNBbGVGcmhOWjdaNVpIVnlVUERLMU5qRlpoOVp4ajhHTUtieUdwYlB5dWJUZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics Stock Soars 21% in Three Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPRFNPSkdxamZCMWM0NDZ0N0dLRXBVU3hWRzJvSnBfUUJ6ME5uak9vOExZTjE4YmdtcG5lS2pjSk5Yb2tYNE02MjVIMmltSzV4aUx6OG1mc3dCNm5zZzgwOWQwYndpUGoxZE93WGpqX3pVcHRXYUpUbWxGV2VKaV9zdlJEbm4wcmVlalUxWFdaV3lxUFMwYU5vdQ?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics Accelerated Approval Bid Puts BEAM-302 At Center Stage", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQRkZkQXhHbGpOUHdCVnpYc1FEUjhUVEY1dkE1M041NnZ3SG51cEJkd05wOW1nazRKd1VldnNSV3o2eW95MWh6Nkdqa3htZGpoTVpYX0RZZS1xM3M2bUltVlE1Y25kcFdPR1Z5elJHU0hodjFycWJvTEg4TFJJalNuSk51QUxvaDdyc0hpWGF0S2ZhajRGYTJESA?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPdkdZdUlyOFdGRWlUdlYxb2Z4NC0zRXk5R0pKUVRtc2VjTFpRMnF5V292UE9YQlYzci1EZXd0N0Y5Y0RUY1dwV1NVSEhwZG9SenRLMmZBamxtVFFVQm5QOXV0ckpEa2xwbUZxY2hCTHV1cnk5MVBEQk9DRllmaWRMZlk2VmdEbFg5d3RxbEZOQjlnd21UM3ZkektLS04xcUE?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQMTNIUVlGY0p2ZWJWQXZvRU1uZDVyVzJXb3NZbGpJbVBlTGpGaHFMSjJTQmJmUExMMTlGYWNER0xtN1NnR1hNcG1Odl90cFF1SVl3MHdSZWJGdGlnRFZIdFpNUjFSNW12UVg2VkF4WVJ0ajJGM1p3MWdiWm5DTmhhZnlOQUlyVjloc1hKbVVqaks4dzFCRkZOYnhEckEycmljNDFJOTBocVBnVExZSUw2TWtIV0g1M3JJT3d3N2doa0RBMGdUdVd5bzd2TzVmZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxObFEyRmcwZ0Y0MXJLaGtoV2VyQm5hb1FrVFlxN2F5V2VMOFpIVHZfNmY1X1NOSi10S1JPZUt4SkI0SGJ3OXZ1LVEteTg1YzRrbGE2eEtVb0pYQ2x0SFZlTkVoZXowNFZ5NXI2RXNXMk11QklGOHV4ZTNWZ2JBOGs4ZUktRHNyN0FVdzQ4WFIxQTZXT2FlZ05sZDhpYlE?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard Capital Mgmt (NASDAQ: BEAM) reports 5.02% ownership stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNZ1A1MHUybFRzTDZaRUREQ2RLdEVzN2R1X2VwTWFueGhsekhibDc5YkdLaXRoRFRFVmQ1MVJlQy15Zld3Yjg3WEVYcVhIdm8yY3lmSHJUTGJVcUN0VEZsNElUZ3JBTkR0VUlyUVpxSGRrQ3ZwNHRiX1czUVZxVFdUVHlKREpnblFRTWtYN091eC15bVY0WlBrakNBaGh6VnZ3RzFHcnRNU3lHUUJ1eElvZ0NWbnZoRFpFVWlaNDhwYnJQOUI5bUlr?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Beam Therapeutics CEO Sells 30,078 Shares in April 2026 Transaction | Stock Update - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNVEExZnZxTHd2d2VtaFFudEdPdWpCeWJzOWNsZ0pZQVRuZHpOZExDRW96bGxkZzB0ZGVEbnFfZnJsNXViYzdmUHRkdnpuaEJ2TjNHYmk2MkI0ZUZsSmVjZGFzeDJrNTBEMWxvVEJIbU1WR3ZYRW5tUE95Y3I1LVBGWEwxWUg0ejVkaF9ScHZIV09LSF9fbTZ5dEg2d0JnejVRTmduUDE4dw?oc=5", "source_name": "IndexBox", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOaWxmNzY4V1Uzc3Zic0JmMDNSQXhxVm9jeFpSdnFLdXlVQlBUYmdKU1NvNFNnNzNMSTctVUtLMGpxamlsQW1wYVp0OWxsbnByOU9XaEZVcXVTaXBfY1pKdEwwSTFubk5ORnlHbWYwY2FINHZfREd5dUw2bFlQYWhUNWNoSWRMdl94WUdVa01LMVJjRUtOdU9MMlZXbHRfRlA3S3c?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here is Why Beam Therapeutics (BEAM) Appears so Attractive", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQa2MwMndwMjZOYVlEbHRLR1VKdGw4YjIwTUUxSVV0MkROMmdMdUxUWGNidU1jb3VMRWs3bWZnVTZuai1rbDlJdFNZQTlpaWNGLUZGdm1IdjlzN1ZEaW5KY0F0aWh5MjVUNVZ6VFRTN2tqZ3oyVUU5a0NGY2lFMjV0TXNVQzZJNDRORmdSajJwQ1A?oc=5", "source_name": "Finviz", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOdkFtZXppRmJOTUt4bEZmZFdKZ0hfdnNJelRtU1lPQVJCYkJETE10Vnd5ck5RakRZbmRpMzE3NWZtMlVtRnJYUFZjdXYtUzIxOGpPLXpoeWJLdnhtODV1OHp1aDMySXhiNW5naUJPaVVNWmNaakQ2bDgtSW11SlE4U2JjVWM2WGIxSEE?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Understanding the Setup: (BEAM) and Scalable Risk", "summary": "This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM), noting weak near and mid-term sentiment despite a positive long-term outlook. It highlights that a breakdown is underway with expected lower levels and elevated downside risk. The analysis provides institutional trading", "url": "https://news.stocktradersdaily.com/news_release/141/Understanding_the_Setup:_BEAM_and_Scalable_Risk_071726093801_1784295481.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-17T09:41:42", "published_display": "17 Jul 2026 09:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics Stock 6-Day Losing Spree: Stock Falls 19%", "summary": "Beam Therapeutics (NASDAQ: BEAM) stock has experienced a significant downturn, falling 19% over a six-day losing streak. This article reports on the stock's recent performance.", "url": "https://www.trefis.com/data/companies/BEAM/no-login-required/hClH0DhR/Beam-Therapeutics-Stock-6-Day-Losing-Spree-Stock-Falls-19-", "source_name": "Trefis", "published_at": "2026-07-16T15:40:25", "published_display": "16 Jul 2026 15:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6 Red Days In A Row: Beam Therapeutics Stock Is Down 19%", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPSHE5Nl9xLXJwNTd4X054WTMzMGNoYlhDb1pNWnVTSGMxdzdXYm5GNGVwZFBVRW1xaXdBM1cybVI5a1BwNTlPV295R3paMXVoSHlwZjF1NFJlWXptSlM1VGk3NjRuUE9xUlhQRFoyd1pEVU04ZnRQV1JJM0V0enVSSVZwUVItYlMwZEhIUDllZmxfd2hMcWwzUy15dGpIU1hiUm1PYTlETWZWdzZQTUhHQ0pPRXdpdw?oc=5", "source_name": "Trefis", "published_at": "2026-07-16T14:32:02+00:00", "published_display": "16 Jul 2026 14:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)", "summary": "Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating for Beam Therapeutics (BEAM) with a $47 target price, citing the limited impact of a recent arbitration resolution on Prime Medicine's PM647. The focus for Beam is now on the execution of its alpha-1 antitr", "url": "https://finance.yahoo.com/healthcare/articles/bank-america-securities-maintains-buy-140153544.html", "source_name": "Market source", "published_at": "2026-07-15T14:19:18", "published_display": "15 Jul 2026 14:19", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics", "summary": "Prime Medicine, Inc. (PRME) announced a positive, binding resolution to its arbitration with Beam Therapeutics regarding their 2019 Collaboration and License Agreement. The Tribunal ruled that Prime Medicine's investigational drug PM647 is within its \"Field\" as defined by the Agr", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-prme-reaches-positive-085317803.html", "source_name": "Market source", "published_at": "2026-07-15T09:12:46", "published_display": "15 Jul 2026 09:12", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE9UcXpfZTFzbjNuSnRscl80ekxhdmIycmN5dzNkZFNjeWVpRFV5dlE3VzRVNDNWOUwxN2w0cm1LYWZkQVlqNkJ4ZDZwdjNpYlBoTFo2MVM4ZU1oQ00?oc=5", "source_name": "ChartMill", "published_at": "2026-07-13T16:55:03+00:00", "published_display": "13 Jul 2026 16:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRME Surges 15% After Winning Arbitration Against Beam \u2014 Clears Path To Human Trials For Its Gene-Editing Drug", "summary": "Prime Medicine (PRME) shares surged 15% after an independent arbitration panel ruled in its favor against Beam Therapeutics (BEAM). The ruling allows Prime to advance its experimental gene-editing drug, PM647, for Alpha-1 Antitrypsin Deficiency, with human trials anticipated in Q", "url": "https://stocktwits.com/news-articles/markets/equity/prme-stock-surges-after-winning-arbitration-against-beam-clears-path-to-human-trials-for-gene-editing-drug/cZmVDItR7NC", "source_name": "Stocktwits", "published_at": "2026-07-12T04:10:08", "published_display": "12 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Sinks 13%: Here\u2019s Why", "summary": "", "url": "https://finance.yahoo.com/m/57b629c0-9b57-300d-bab5-69e9c31cc364/kyverna-therapeutics-sinks.html", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T19:59:59+00:00", "published_display": "10 Jul 2026 19:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics Inc. (BEAM) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Beam Therapeutics Inc. (BEAM) stock, showing a current price of $36.02, up $0.20 (0.57%). It also notes that there are no analyst ratings or earnings information currently available for BEAM. The page is hosted by a platform focused o", "url": "https://timothysykes.com/quote/BEAM/", "source_name": "timothysykes.com", "published_at": "2026-07-09T23:10:57", "published_display": "09 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/beam-therapeutics-beam-faces-aatd-201410556.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T20:14:10+00:00", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable (PRME)", "summary": "Prime Medicine (PRME) recently won an arbitration ruling against Beam Therapeutics regarding its PM647 gene editing program for AATD, causing a surge in its stock. While Prime Medicine's platform offers precision, its programs are still preclinical, with clinical data expected in", "url": "https://seekingalpha.com/article/4920898-prime-medicine-beats-beam-therapeutics-in-patent-dispute-but-both-are-investable", "source_name": "Seeking Alpha", "published_at": "2026-07-09T14:44:28", "published_display": "09 Jul 2026 14:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM) On Tribunal Clarity Is It A Buying Opportunity Or Priced In", "summary": "Beam Therapeutics (BEAM) recently saw its share price rise after a tribunal clarified its collaboration with Prime Medicine, removing monetary risk and clarifying program rights. While narrative analysis suggests the stock is 75% undervalued with a $150 fair value based on its \"m", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/beam-therapeutics-beam-on-tribunal-clarity-is-it-a-buying-op", "source_name": "Simply Wall Street", "published_at": "2026-07-09T10:40:04", "published_display": "09 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BEAM Reiterated by B of A Securities -- Price Target Maintained at $47", "summary": "B of A Securities has reiterated a \"Buy\" rating for Beam Therapeutics (BEAM), maintaining a price target of $47.00, despite the stock being currently valued as 29.6% overvalued by GuruFocus's GF Value\u2122. The company's GF Score\u2122 is 69/100, showing strong financial stability and mom", "url": "https://www.gurufocus.com/news/8950290/beam-reiterated-by-b-of-a-securities-price-target-maintained-at-47", "source_name": "GuruFocus", "published_at": "2026-07-08T23:11:21", "published_display": "08 Jul 2026 23:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-receives-favorable-ruling-180823492.html", "source_name": "MT Newswires", "published_at": "2026-07-08T18:08:23+00:00", "published_display": "08 Jul 2026 18:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise", "summary": "Prime Medicine received a favorable ruling in a license arbitration against Beam Therapeutics, leading to a rise in Prime Medicine's shares. This article provides a brief update on this development and lists recent news related to Beam Therapeutics, including its inclusion in var", "url": "https://www.marketscreener.com/news/prime-medicine-receives-favorable-ruling-in-beam-therapeutics-license-arbitration-shares-rise-ce7f5ed9dd88f723", "source_name": "marketscreener.com", "published_at": "2026-07-08T18:09:00", "published_display": "08 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-receives-favorable-ruling-160256429.html", "source_name": "MT Newswires", "published_at": "2026-07-08T16:02:56+00:00", "published_display": "08 Jul 2026 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine wins binding arbitration against Beam Therapeutics", "summary": "Prime Medicine has won a binding legal arbitration dispute against Beam Therapeutics regarding the genetic asset PM647, confirming the development platform falls entirely within Prime Medicine's contractual field. The company will face zero damage penalties and plans to file clin", "url": "https://grafa.com/en/news/united-states/prime-medicine-arbitration-win-beam-therapeutics", "source_name": "grafa.com", "published_at": "2026-07-08T16:11:21", "published_display": "08 Jul 2026 16:11", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Beam Therapeutics stock sliding today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZlA3UmdRSW5nTW5lUFJqdVBueDN2TjRmSVNOSnZrLWFEWVJ2QW1WOWN6ZzdUQXhicllHakI4d3o1S1pVQk15bTR1X3RIeG9ZVkJPcFRxTWZtdFVxZFBoUHl6LUtlMy1ZVDIydDBjQUl6VHF6a1Y1VkZ0aktFVXhYT0dTNkZ5em0zQ29DMnlxQW40dV94SURpVjJ4WWd6clBKYVp6M08xY0Q2Zw?oc=5", "source_name": "Investing.com", "published_at": "2026-07-08T14:56:42+00:00", "published_display": "08 Jul 2026 14:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/prime-medicine-announces-positive-resolution-120000702.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T12:00:00+00:00", "published_display": "08 Jul 2026 12:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQM0lEeVE2U2lnc1ZjdmdjejktdmtuX29VV3Y2U084UDBhdldtakp0WXI4LUIwVVNPX09LanJMWnZEdHVWUWhGR29fcUlOOFMyNUFsMFdoNk5oaGZVVUZiUXZMeUE4UnA5dllkWlVrZjNRQmZZTmliSGhvSExMYldwWTZIWFJKeDd6eFZvRkpTd3RoMDNNV0xtdEZ0dXUtMHF5blFpcEhfek5JdkRVOUVFU0tFeU9HWDFFR1E1SU1JOUM?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Russell Value Index Additions Could Be A Game Changer For Beam Therapeutics (BEAM)", "summary": "Beam Therapeutics (BEAM) was recently added to several Russell Value indices in late June 2026, which is expected to influence trading activity as index-tracking funds adjust their portfolios. While this broad inclusion may impact liquidity and ownership, the company's investment", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/russell-value-index-additions-could-be-a-game-changer-for-be", "source_name": "Simply Wall Street", "published_at": "2026-07-07T07:40:52", "published_display": "07 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics stock hits 52-week high at 36.89 USD", "summary": "Beam Therapeutics Inc. (BEAM) stock has surged to a new 52-week high of $36.89, currently trading at $37.02, reflecting a 90.88% increase over the past year. This growth is attributed to investor confidence in its genetic medicine approaches and recent positive developments, incl", "url": "https://www.investing.com/news/company-news/beam-therapeutics-stock-hits-52week-high-at-3689-usd-93CH-4777036", "source_name": "Investing.com", "published_at": "2026-07-06T16:39:44", "published_display": "06 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC Reduces Stake in Beam Therapeutics Inc.", "summary": "FMR LLC significantly reduced its stake in Beam Therapeutics Inc. by 86.38%, selling over 10 million shares at $35.24 each. Despite this reduction, Beam Therapeutics still represents 1.65% of FMR LLC's holdings, indicating continued belief in the biotechnology company. Beam Thera", "url": "https://www.gurufocus.com/news/8944610/fmr-llc-reduces-stake-in-beam-therapeutics-inc", "source_name": "GuruFocus", "published_at": "2026-07-04T00:39:41", "published_display": "04 Jul 2026 00:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (NASDAQ: BEAM) CMO sells 373 shares for tax withholding", "summary": "Amy Simon, Chief Medical Officer at Beam Therapeutics Inc. (NASDAQ: BEAM), sold 373 shares of common stock for $34.73 each. This non-discretionary transaction was undertaken to cover tax withholding obligations associated with the vesting of restricted stock units granted under t", "url": "https://www.stocktitan.net/sec-filings/BEAM/form-4-beam-therapeutics-inc-insider-trading-activity-11ef9f696223.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:09:15", "published_display": "02 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Following FDA Clearance, Is Beam Therapeutics (BEAM) Already Priced In?", "summary": "Beam Therapeutics (BEAM) has seen its investigational new drug application for BEAM-304 cleared by the FDA, allowing a Phase 1/2 trial to proceed for phenylketonuria patients. Despite a strong share price performance over the past year, the article explores whether the stock, cur", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/following-fda-clearance-is-beam-therapeutics-beam-already-pr", "source_name": "Simply Wall Street", "published_at": "2026-07-02T10:09:15", "published_display": "02 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BEAM - Beam Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial overview for Beam Therapeutics Inc. (BEAM). It includes detailed financial metrics such as market capitalization, income, sales, EPS, P/E ratios, employee count, and stock performance data, offering a snapsh", "url": "https://finviz.com/stock?t=BEAM&p=d&ty=lf&b=2&r=m6&page=9", "source_name": "Finviz", "published_at": "2026-07-02T10:09:15", "published_display": "02 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM) CEO exercises options and sells 50K shares under plan", "summary": "Beam Therapeutics (BEAM) CEO John M. Evans exercised options for 50,000 shares and subsequently sold the same number of shares through open-market transactions at weighted average prices in the mid-$30s. These transactions were carried out under a pre-arranged Rule 10b5-1 trading", "url": "https://www.stocktitan.net/sec-filings/BEAM/form-4-beam-therapeutics-inc-insider-trading-activity-092139809100.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:39:41", "published_display": "01 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BEAM (NASDAQ: BEAM) insider files to sell 25,000 shares via option exercise", "summary": "An insider at Beam Therapeutics Inc. (NASDAQ: BEAM) filed a Form 144 to sell 25,000 common shares through a stock option exercise on June 29, 2026. This regulatory filing indicates an intent to sell, and similar prior transactions by John M. Evans were detailed, including sales i", "url": "https://www.stocktitan.net/sec-filings/BEAM/144-beam-therapeutics-inc-sec-filing-72b474ad91a7.html", "source_name": "Stock Titan", "published_at": "2026-06-30T08:42:59", "published_display": "30 Jun 2026 08:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "25,000-share Rule 144 notice by BEAM (NASDAQ: BEAM) shows option exercise and prior sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOX3J6ZFEzV0c5ZFpvdXRPbjdPWGd6QTVQclRYNnp0ZUJnRzVBYWNaME1nQ0dKcG5zS1pWYzNWNzBrYWxzMnphLS1xLTJnODJwQUFrRW1IaG1aOW5saGNFWC1vZnNoblR5S19XSkhXZV9XSUtnY2lCU2hIV1lSNW1PZzVwVTVJZ3R2TUt3WEd3alpJWkZOTUxTa1cxM2VfSnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics(BEAM.US) 10% Shareholder Sells US$10.04 Million in Common Stock", "summary": "A 10% shareholder of Beam Therapeutics (BEAM.US) recently sold a significant amount of common stock, totaling US$10.04 million. This transaction indicates a notable insider sale that could be of interest to investors tracking company performance.", "url": "https://www.moomoo.com/news/post/72206765/beam-therapeutics-beamus-10-shareholder-sells-us-10-04-million", "source_name": "Moomoo", "published_at": "2026-06-29T20:42:59", "published_display": "29 Jun 2026 20:42", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC sells $10.04 million in Beam Therapeutics shares", "summary": "FMR LLC, a major shareholder, recently sold Beam Therapeutics Inc. (NASDAQ:BEAM) shares worth approximately $10.04 million in late June, with sales occurring at weighted average prices between $35.12 and $35.26. The stock is trading near its 52-week high after a 107% gain over th", "url": "https://www.investing.com/news/insider-trading-news/fmr-llc-sells-1004-million-in-beam-therapeutics-shares-93CH-4766015", "source_name": "Investing.com", "published_at": "2026-06-29T18:40:37", "published_display": "29 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC (BEAM) trims Beam Therapeutics stake with 284,860-share open-market sale", "summary": "FMR LLC, a significant owner of Beam Therapeutics Inc., reported trimming its stake by selling a total of 284,860 common shares through indirect open-market sales. These sales, executed via F-Prime Capital Partners Healthcare Fund V LP on June 25th and 26th, 2026, were valued at ", "url": "https://www.stocktitan.net/sec-filings/BEAM/form-4-beam-therapeutics-inc-insider-trading-activity-a69c1d542de0.html", "source_name": "Stock Titan", "published_at": "2026-06-29T18:40:37", "published_display": "29 Jun 2026 18:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How FDA Clearance of BEAM-304\u2019s Platform Trial for PKU May Impact Beam Therapeutics (BEAM) Investors", "summary": "Beam Therapeutics announced FDA clearance for its BEAM-304 IND application for PKU, featuring a platform-style trial designed to test multiple base editors within a single clinical framework. While this strengthens Beam's in vivo liver editing story and provides a near-term clini", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/how-fda-clearance-of-beam-304s-platform-trial-for-pku-may-im", "source_name": "Simply Wall Street", "published_at": "2026-06-26T22:10:30", "published_display": "26 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics, Inc. Actuals & Estimates (NASDAQ:BEAM)", "summary": "This article provides financial actuals and estimates for Beam Therapeutics Inc. (NASDAQ:BEAM), offering insights into its stock performance, analyst forecasts, and company financials. It details BEAM's current stock price, market capitalization, historical highs and lows, and up", "url": "https://www.tradingview.com/symbols/NASDAQ-BEAM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:40:37", "published_display": "26 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics, Inc. Actuals & Estimates (BMV:BEAM)", "summary": "This article provides financial actuals and estimates for Beam Therapeutics, Inc. (BEAM) traded on the Mexican Stock Exchange (BMV). It details current stock price, historical performance, analyst forecasts, volatility, market capitalization, and upcoming earnings reports. Key fi", "url": "https://www.tradingview.com/symbols/BMV-BEAM/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T05:09:43", "published_display": "26 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM) Short Interest & Short Float | Updated Jun 2026", "summary": "Beam Therapeutics (BEAM) saw its short interest increase by 31.94% to 28.31 million shares as of June 15, 2026, representing 28.60% of its public float. The short interest ratio or \"days to cover\" stands at 14.2, indicating strong pessimism among investors. This article provides ", "url": "https://www.marketbeat.com/stocks/NASDAQ/BEAM/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-25T20:11:06", "published_display": "25 Jun 2026 20:11", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Beam Therapeutics Inc. \u2013 NASDAQ:BEAM", "summary": "The article focuses on the \"Price to sales forward\" metric for Beam Therapeutics Inc. (NASDAQ: BEAM). It provides a high-level view of this financial data point, indicating it is one of the many financial details available for the company on the TradingView platform. The content ", "url": "https://www.tradingview.com/symbols/NASDAQ-BEAM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:41:56", "published_display": "25 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (BEAM) That Institutions Follow", "summary": "This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM) through the lens of technical signals, highlighting strong sentiment across all horizons and an exceptional risk-reward setup targeting a 16.8% gain. It details three AI-generated trading strategies\u2014Position, Momentum Br", "url": "https://news.stocktradersdaily.com/news_release/101/The_Technical_Signals_Behind_BEAM_That_Institutions_Follow_062526010601_1782363961.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-25T01:06:00", "published_display": "25 Jun 2026 01:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM) Could Be 78% Undervalued As FDA Clears BEAM 304", "summary": "Beam Therapeutics (BEAM) is under investor focus after the FDA cleared its investigational new drug application for BEAM-304, an in vivo base editing therapy. The stock is currently trading at US$33.20, while a narrative fair value suggests it could be 77.9% undervalued at $150. ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/beam-therapeutics-beam-could-be-78-undervalued-as-fda-clears", "source_name": "Simply Wall Street", "published_at": "2026-06-24T17:40:20", "published_display": "24 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 93, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics president exercises 35,505 options | BEAM Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNcGItMFJvTGZ3d2p4RGlSdnpkY1RpcG9pNG80cm5SZ283VHp1VHRRdmk5QnZxT3Y3eTFMaXI5dGxuWjFySkRhdGpsQS1Nb2tMRFNVc0c4WjNaS2ZLdHpRX2FIZmdYUHhUcUFnRkFvSmxKTmpXTVlHUlVSTmduT2pQS0NlcElvMEpUMHNBbGVGcmhOWjdaNVpIVnlVUERLMU5qRlpoOVp4ajhHTUtieUdwYlB5dWJUZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics Stock Soars 21% in Three Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPRFNPSkdxamZCMWM0NDZ0N0dLRXBVU3hWRzJvSnBfUUJ6ME5uak9vOExZTjE4YmdtcG5lS2pjSk5Yb2tYNE02MjVIMmltSzV4aUx6OG1mc3dCNm5zZzgwOWQwYndpUGoxZE93WGpqX3pVcHRXYUpUbWxGV2VKaV9zdlJEbm4wcmVlalUxWFdaV3lxUFMwYU5vdQ?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics Accelerated Approval Bid Puts BEAM-302 At Center Stage", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQRkZkQXhHbGpOUHdCVnpYc1FEUjhUVEY1dkE1M041NnZ3SG51cEJkd05wOW1nazRKd1VldnNSV3o2eW95MWh6Nkdqa3htZGpoTVpYX0RZZS1xM3M2bUltVlE1Y25kcFdPR1Z5elJHU0hodjFycWJvTEg4TFJJalNuSk51QUxvaDdyc0hpWGF0S2ZhajRGYTJESA?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPdkdZdUlyOFdGRWlUdlYxb2Z4NC0zRXk5R0pKUVRtc2VjTFpRMnF5V292UE9YQlYzci1EZXd0N0Y5Y0RUY1dwV1NVSEhwZG9SenRLMmZBamxtVFFVQm5QOXV0ckpEa2xwbUZxY2hCTHV1cnk5MVBEQk9DRllmaWRMZlk2VmdEbFg5d3RxbEZOQjlnd21UM3ZkektLS04xcUE?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQMTNIUVlGY0p2ZWJWQXZvRU1uZDVyVzJXb3NZbGpJbVBlTGpGaHFMSjJTQmJmUExMMTlGYWNER0xtN1NnR1hNcG1Odl90cFF1SVl3MHdSZWJGdGlnRFZIdFpNUjFSNW12UVg2VkF4WVJ0ajJGM1p3MWdiWm5DTmhhZnlOQUlyVjloc1hKbVVqaks4dzFCRkZOYnhEckEycmljNDFJOTBocVBnVExZSUw2TWtIV0g1M3JJT3d3N2doa0RBMGdUdVd5bzd2TzVmZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxObFEyRmcwZ0Y0MXJLaGtoV2VyQm5hb1FrVFlxN2F5V2VMOFpIVHZfNmY1X1NOSi10S1JPZUt4SkI0SGJ3OXZ1LVEteTg1YzRrbGE2eEtVb0pYQ2x0SFZlTkVoZXowNFZ5NXI2RXNXMk11QklGOHV4ZTNWZ2JBOGs4ZUktRHNyN0FVdzQ4WFIxQTZXT2FlZ05sZDhpYlE?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard Capital Mgmt (NASDAQ: BEAM) reports 5.02% ownership stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNZ1A1MHUybFRzTDZaRUREQ2RLdEVzN2R1X2VwTWFueGhsekhibDc5YkdLaXRoRFRFVmQ1MVJlQy15Zld3Yjg3WEVYcVhIdm8yY3lmSHJUTGJVcUN0VEZsNElUZ3JBTkR0VUlyUVpxSGRrQ3ZwNHRiX1czUVZxVFdUVHlKREpnblFRTWtYN091eC15bVY0WlBrakNBaGh6VnZ3RzFHcnRNU3lHUUJ1eElvZ0NWbnZoRFpFVWlaNDhwYnJQOUI5bUlr?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics CEO Sells 30,078 Shares in April 2026 Transaction | Stock Update - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNVEExZnZxTHd2d2VtaFFudEdPdWpCeWJzOWNsZ0pZQVRuZHpOZExDRW96bGxkZzB0ZGVEbnFfZnJsNXViYzdmUHRkdnpuaEJ2TjNHYmk2MkI0ZUZsSmVjZGFzeDJrNTBEMWxvVEJIbU1WR3ZYRW5tUE95Y3I1LVBGWEwxWUg0ejVkaF9ScHZIV09LSF9fbTZ5dEg2d0JnejVRTmduUDE4dw?oc=5", "source_name": "IndexBox", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOaWxmNzY4V1Uzc3Zic0JmMDNSQXhxVm9jeFpSdnFLdXlVQlBUYmdKU1NvNFNnNzNMSTctVUtLMGpxamlsQW1wYVp0OWxsbnByOU9XaEZVcXVTaXBfY1pKdEwwSTFubk5ORnlHbWYwY2FINHZfREd5dUw2bFlQYWhUNWNoSWRMdl94WUdVa01LMVJjRUtOdU9MMlZXbHRfRlA3S3c?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Beam Therapeutics (BEAM) Appears so Attractive", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQa2MwMndwMjZOYVlEbHRLR1VKdGw4YjIwTUUxSVV0MkROMmdMdUxUWGNidU1jb3VMRWs3bWZnVTZuai1rbDlJdFNZQTlpaWNGLUZGdm1IdjlzN1ZEaW5KY0F0aWh5MjVUNVZ6VFRTN2tqZ3oyVUU5a0NGY2lFMjV0TXNVQzZJNDRORmdSajJwQ1A?oc=5", "source_name": "Finviz", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOdkFtZXppRmJOTUt4bEZmZFdKZ0hfdnNJelRtU1lPQVJCYkJETE10Vnd5ck5RakRZbmRpMzE3NWZtMlVtRnJYUFZjdXYtUzIxOGpPLXpoeWJLdnhtODV1OHp1aDMySXhiNW5naUJPaVVNWmNaakQ2bDgtSW11SlE4U2JjVWM2WGIxSEE?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 61, "sentiment_summary": {"positive": 15, "negative": 9, "neutral": 37, "score": 52, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.65, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}], "positive_events": 15, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 32.68, "latest_week": "2026-07-10", "one_week_move": -6.1, "four_week_move": 12.6, "twelve_week_move": 4.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.121035, "market_dynamics_buy_signal": false, "relative_strength": 7.885242, "fair_value_gap": 28.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 43.6806, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.1% over one week, +12.6% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 7}, {"label": "Simply Wall Street", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Trefis", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 12}, {"label": "Regulatory and legal", "count": 6}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 3}, {"label": "Deals and strategy", "count": 3}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.1% over one week, +12.6% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Understanding the Setup: (BEAM) and Scalable Risk"}], "updated_at": "2026-07-18T00:31:13.211766+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}